Related Experiment Video
Updated: May 24, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Prevention. Aspirin in primary prevention--good news and bad news
Charles H Hennekens1, Colin Baigent
1Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Research Park, Boca Raton, FL 33431, USA. chenneke@fau.edu
Abstract:
The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Preventive Healthcare Services
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
Coronary Artery Disease V: Interprofessional Care
